Regimen | No. of ALL | Mean age (range) | Donor | Stem cell source | Disease status at HSCT | Survival rate | Relapse rate | TRM/NRM | aGVHD | cGVHD | Remarks | Reference |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Flu 90–150 mg/m2 + Mel 140 mg/m2 | 27 | 50 (18–63) | MRD | BM | CR1: 3 | 2-Y OS: 31 % | 49 % | TRM: 23 % | Gr.≧II: 48 % | 67 % | A small sample sized retrospective study; GVL effect was exhibited. | Martino R, et al. Haematologica 2003;88: 555. |
Flu + Mel+ Ara-C 2 g/m2 | MMRD | PB | CR2/3:10 | GVHD+: 35 % | Limt.: 39 % | |||||||
Flu + 2 Gy TBI | MUD | PR2:1 | GVHD-: 70 % | Ext.: 28 % | ||||||||
Flu + Mel+ CAMPATH-1H 200 mg/kg | MMUD | Non-CR: 12 | ||||||||||
Flu + CY 60 mg/kg+ Thiotpa 10 mg/kg | ||||||||||||
Flu 30 mg/m2 × 6 +4 Gy TBI/ATG 10 mg/kg/d × 4 | 97 | 38 (15–66) | MRD | BM | CR1:28 | 2-Y OS: 52 % | 40 % | CR1, NRM: 18 % | Gr.≧II: 33 % | 37 % | Factors for better OS were CR1, chronic GVHD, and female donor according to a retrospective study. | Mohty M, et al. Haematologica 2008; 93: 303. |
Flu + BU 8 mg/kg | MUD | PB | CR2/3: 30 | 27 % | 63 % | CR2/CR3, NRM: 17 % | ||||||
Flu + Mel | Non-CR: 39 | 20 % | 49 % | More advanced stage, NRM: 44 % | ||||||||
Flu + CY | ||||||||||||
Flu 25 mg/m2 × 5+ Mel 140 mg/m2 × 1 | 24 | 48 (23–68) | MRD | PB | CR1: 11 | 2-Y OS: 62 % | 21 % | NRM: 22 % | Gr.≧II: 63 % | 75 % | RIC HSCT might offer a promising option for high risk ALL patients not eligible for standard myeloablative transplantation according to a. retrospective study. | Stein AS, et al. Biol. Blood Marrow Transplant. 2009; 15: 1407. |
MUD | CR2: 5 | Limit.: 21 % | ||||||||||
≧CR3: 3 | Ext.: 54 % | |||||||||||
Non-CR 5 | ||||||||||||
Flu 40 mg/m2 × 5+ CY 50 mg/kg+ TBI 2 Gy | 22 (high risk) | 49 (24–68) | MRD | PB | CR1: 12 | 3-Y OS: 50 % | 36 % | TRM: 27 % | Gr.≧II:55 % | 45 % | In a small sample sized prospective study, HSCT at CR1 showed an excellent outcome, but the relapse rate was high. | Bachanova V, et al. Blood 2009; 113: 2902. |
MUD | CB | ≧CR2: 10 | Gr.≧III: 20 % | Ext.: 32 % | ||||||||
Flu 30 mg/m2 × 5 +Mel 70 mg/m2 × 2 +/−ATG 2.5 mg/kg | 37 | 45 (15–63) | MRD | PB | CR1: 30 | 3-Y OS: 64 % | 20 % | NRM: 18 % | Gr.≧II: 43 % | 66 % | Transplant in CR1 showed a better outcome in a prospective phase II study. GVL effect was induced in cGVHD. | Cho B-S, et al. Leukemia 2009;23:1763. |
MUD | BM | CR2: 7 | Limit: 28 % | |||||||||
MMUD | Ext: 38 % | |||||||||||
BU 9 mg/kg or less + Mel 150 mg/m2 or less+ TBI >5 Gy or fractionated | 93 | 45 (17–66) | MRD: 30 | PB: 68 | CR1: 55 | 3-Y OS: 38 % (RIC) | 35 % (RIC) | RIC | TRM rate in RIC was almost the same as that in MAC, but the relapse rate was higher in RIC (35 % vs 26 %) according to a retrospective study. | Marks DI, et al. Blood 2010;116:366 | ||
TBI >8 Gy | MUD: 36 | BM: 25 | CR2: 38 | 3-Y OS: 43 % (MAC) | 26 % (MAC) | TRM: 32 % | Gr.≧II: 39 % | 34 % | ||||
Flu + TBI 2 Gy | PMMUD: 20 | 3-Y DFS: 32 % (RIC) | MAC | |||||||||
Others | MMUD: 5 | 3-Y DFS: 41 % (MAC) | TRM: 33 % | Gr.≧II: 46 % | 42 % | |||||||
UD: 2 |